3 Japanese Dividend Stocks With Yields Above 3% And Earnings Support

Global bond yields are climbing as inflation worries linger, which has pushed many income seekers to rethink how they earn reliable cash flow from their portfolios. That is where high quality dividend powerhouses come in. These stocks offer yields above 5% that company earnings currently cover. This article highlights three stocks from the Dividend Powerhouses screener that stand out for investors who want robust income with discipline around payouts.

The three stocks covered below are just a starting sample. The full Dividend Powerhouses screen surfaced 457 more companies with similarly compelling income stories that are not included here.

If you want to move straight from ideas to a workable watchlist, head into the Dividend Powerhouses (3%+ Yield) screener to identify candidates, analyze their dividend profiles, and focus on the income plays that best fit your goals.

Canon (TSE:7751)

Overview: Canon is a global electronics company that develops, manufactures, and services a wide range of printing, medical imaging, cameras, and industrial equipment for businesses and consumers across Japan, the Americas, Europe, Asia, and Oceania.

Operations: Canon generates most of its revenue from its Printing Business Unit at about ¥2.5t, followed by Imaging at about ¥1.1t, Medical at about ¥579b, Industrial at about ¥347b, and smaller contributions from other activities and internal eliminations.

Market Cap: ¥3.95t

Income focused investors may want to keep Canon on the radar because it combines a global hardware footprint with earnings that management and analysts describe as high quality, a rising net margin of 7.4%, and a P/E that sits below many peers. The company is putting meaningful cash behind shareholders through a sizeable buyback that retired more than 4% of shares in the first half of 2026, while half year results show higher revenue and earnings per share. On the other hand, it has a dividend record described as unstable and forecasts for slower growth and modest ROE, along with questions around board independence and reliance on external borrowings. That mix of improving profitability, shareholder returns, and governance trade offs sets up a richer story for dividend hunters to unpack.

Canon’s rising net margin and ongoing buyback suggest that headline metrics may not fully reflect its income potential. See how the 4 key rewards and 1 important warning sign could tilt the risk reward balance in an unexpected way.

Build your own dividend powerhouse shortlist

Canon and the other stocks in this list all came from a single screener, but the real edge is in shaping filters around what matters most to you. Use our flexible Screener to mix factors like dividends, balance sheet strength, valuation and risks, or jump straight into our curated Investing Ideas for ready made starting points.

Tokio Marine Holdings (TSE:8766)

Overview: Tokio Marine Holdings is a global insurance group that offers a wide range of non life and life insurance products, retirement services, and risk solutions for everything from cars and homes to natural catastrophes, cyber incidents, and large commercial projects across Japan, the United States, and other international markets.

Operations: Tokio Marine Holdings generates most of its revenue from Overseas Insurance Business at about ¥5.4t, followed by Domestic Property and Casualty Insurance at about ¥3.2t, Domestic Life Insurance at about ¥445b, and Solution and Other Business at about ¥328b.

Market Cap: ¥14.3t

Tokio Marine Holdings may interest dividend focused investors because it offers a 3.25% yield, ongoing share buybacks, and a stated push toward leaner operations and higher returns on equity, together with reported growth in earnings per share in recent quarters. The company is also pushing into areas such as disaster resilience and carbon insurance, illustrated by its investment in UK based carbon insurer Kita and new products for carbon credit buyers, which adds a forward looking angle to an established insurance franchise founded in 1879. At the same time, margin erosion, high reliance on external borrowing, and relatively high valuation multiples mean investors may need to weigh the income and strategic plans against funding and underwriting risks that are still playing out.

Tokio Marine’s combination of overseas scale, carbon insurance initiatives, and buybacks can appear to signal growth momentum that the headline P/E only partly reflects. The full 3 key rewards and 1 important warning sign could reveal what that margin erosion is really indicating.

Daiichi Sankyo Company (TSE:4568)

Overview: Daiichi Sankyo Company is a global pharmaceutical company focused on cancer, cardiovascular, metabolic and neurological diseases, with a key emphasis on antibody drug conjugate therapies such as Enhertu and Datroway, as well as a broad portfolio of treatments for conditions from acute myeloid leukemia and iron deficiency to migraine and osteoporosis.

Operations: Daiichi Sankyo Company currently generates all of its reported revenue, about ¥2.22t, from its Pharmaceutical Operation segment.

Market Cap: ¥4.97t

Income investors who want exposure to healthcare themes may find Daiichi Sankyo Company interesting because it combines a 3.66% yield with oncology franchises like Enhertu and Datroway, guidance for FY2026, and expanding reach through approvals and reimbursement in markets such as China and the EU. Analysts currently expect earnings growth above the wider Japanese market and see the stock trading below some fair value estimates, although the P/E sits above the sector average. The catch is reliance on a relatively small group of cancer drugs, high R&D spending, pressure on margins and the need to fund expansion with sizeable borrowing. That balance between oncology momentum and concentration risk is where the income story becomes more nuanced.

Daiichi Sankyo Company sits at the crossroads of oncology momentum and concentration risk. The analyst forecasts for Daiichi Sankyo Company shows how current expectations line up against that cancer drug reliance and where the story could sharply surprise investors next.

Seeking Alternatives Before The Crowd Moves

Fresh ideas can move fast. Some stocks build quiet momentum, others risk being caught once prices start flying or dropping. Scan these under the radar sets while it matters and consider your options early.

• Spot companies quietly building an edge before they trend on headlines by scanning the curated 68 high quality undiscovered gems that are still under the radar for now.
• Track businesses involved in the next leg of AI development and see which ones already generate profits through the focused 76 profitable AI stocks that aren't just burning cash.
• Anchor your watchlist with companies that may better handle shocks by running a filter across the carefully vetted 60 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com